HLA-G is known to up-regulate PD-1 in tumor infiltrating T lymphocytes, leading to a potential antitumor synergy when combining anti-PD-1/PD-L1 antibodies with HLA-G targeted therapies [94]. Here, PDCD1 is linked to neoplasm.